We apply a suite of high-dimensional technologies to investigate the local, cellular, and systemic responses in CTCL patients receiving either mono- or combination anti-PD-1 plus interferon-gamma (IFN-γ) therapy. Here, IFNG is linked to primary cutaneous T-cell non-Hodgkin lymphoma.